Cx 601

Drug Profile

Cx 601

Alternative Names: Adipose-derived allogenic stem cell therapy - TiGenix; Cx601; eASC therapy - TiGenix

Latest Information Update: 04 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cellerix
  • Developer La Fundacion para la Investigacion Biomedica del Hospital Universitario La Paz; Takeda; TiGenix
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rectal fistula
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Rectal fistula
  • No development reported Rectovaginal fistula

Most Recent Events

  • 30 Jun 2017 TiGenix initiates enrolment in a phase III trial for Rectal fistula in Europe and Israel
  • 20 Jun 2017 Preregistration for Rectal fistula (Treatment-experienced) in Switzerland (Intralesional)
  • 09 Apr 2017 Updated efficacy and adverse events data from the phase III ADMIRE-CD trial in Rectal fistula released by TiGenix
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top